metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced RCC (mRCC) - 2nd line (L2) 2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cabozantinib
nivolumab based treatment
nivolumab alone

versus all
vs mTOR inhibitors
vs everolimus
vs VEGF(R) inhibitor
vs cabozantinib

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open